EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exceptional and durable response with pembrolizumab in a patient with microsatellite stable metastatic castrate-resistant prostate cancer: High tumor mutational burden and circulating tumor DNA clearance as predictive biomarkers

Cherry Au, Changtai Tian, Revathi Kollipara, David Vanderweele, Trevor Christ, Andrew Kelly, Alan Tan

Oncology and Translational Medicine · 2025-08 · 11 (4) · 195-197

DOI: 10.1097/ot9.0000000000000089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology and Translational Medicine, online erschienen am 25.06.2025. Verfasst von Cherry Au und 6 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emerging biomarkers, such as tumor mutational burden and circulating tumor DNA (ctDNA), offer promising tools for identifying patients with prostate cancer who may benefit from immune checkpoint inhibitor therapy. This report describes an exceptional response to pembrolizumab in a patient with a microsatellite stability metastatic castration-resistant prostate cancer and ultrahigh tumor mutational burden. Additionally, this case further emphasizes the utility of ctDNA for monitoring molecular residual disease in patients whose disease burden is not adequately reflected by prostate-specific antigen levels and supports the use of ctDNA as a biomarker for personalized treatment monitoring and guiding treatment de-escalation.

Zitieren

APA

Au, C., Tian, C., Kollipara, R., Vanderweele, D., Christ, T., Kelly, A., & Tan, A. (2025). Exceptional and durable response with pembrolizumab in a patient with microsatellite stable metastatic castrate-resistant prostate cancer: High tumor mutational burden and circulating tumor DNA clearance as predictive biomarkers. Oncology and Translational Medicine, 11(4), 195-197. https://doi.org/10.1097/ot9.0000000000000089

Vancouver

Au C, Tian C, Kollipara R, Vanderweele D, Christ T, Kelly A, et al. Exceptional and durable response with pembrolizumab in a patient with microsatellite stable metastatic castrate-resistant prostate cancer: High tumor mutational burden and circulating tumor DNA clearance as predictive biomarkers. Oncology and Translational Medicine. 2025;11(4):195-197. doi:10.1097/ot9.0000000000000089

BibTeX
@article{Au2025,
  author = {Au, Cherry and Tian, Changtai and Kollipara, Revathi and Vanderweele, David and Christ, Trevor and Kelly, Andrew and Tan, Alan},
  title = {Exceptional and durable response with pembrolizumab in a patient with microsatellite stable metastatic castrate-resistant prostate cancer: High tumor mutational burden and circulating tumor DNA clearance as predictive biomarkers},
  journal = {Oncology and Translational Medicine},
  year = {2025},
  volume = {11},
  number = {4},
  pages = {195--197},
  doi = {10.1097/ot9.0000000000000089}
}
Kostenlos starten →